Clinical trials
Immunity clinical trials
Below are recruiting immunity clinical trials, each written for real people, not researchers. We’re tracking 1,065 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06708507Recruiting
Immune cells in graft-versus-host disease
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
Guangzhou, Other (Non U.s.)Ages 18–65 - NCT03591302RecruitingPhase 1
Stem cell transplant to stop anti-rejection drugs after kidney transplant
This study tries to use a stem cell transplant from your original kidney donor to help your body accept the kidney without needing lifelong anti-rejection drugs. You must have a perfectly matched sibling donor who is still available.
Palo Alto, CaliforniaAges 18 years+ - NCT07024238Enrolling by invitation
Short-chain fatty acid supplement for kidney transplant patients
This study tests whether taking a short-chain fatty acid (a type of fiber-like substance) supplement can improve gut health in people who have had a kidney transplant. It may help keep the transplant working well.
Martin, SlovakiaAges 18 years+ - NCT06479304Recruiting
Hydroxychloroquine plus prednisone for ANA-positive ITP
This study tests whether a combination of hydroxychloroquine (HCQ) and prednisone (a steroid) is safe and effective for treating immune thrombocytopenia (ITP) in people who have a positive ANA blood test. It may be an option for those with low platelets and bleeding risk.
Shanghai, Shanghai MunicipalityAges 15–99 - NCT07203365RecruitingPhase 3
RSV vaccine study for older adults in Sweden
This study tests a vaccine called Arexvy to see if it protects older adults from RSV, a virus that can cause serious lung infections. You must be born between 1965 and 1960 or before 1945, live in Sweden, and be medically stable.
SaltsjöbadenAges 60 years+ - NCT04430530RecruitingPhase 1/Phase 2
4SCAR-T therapy for B-cell cancer after CD19 treatment
This trial tests a new type of CAR T-cell therapy (4SCAR-T) for people whose B-cell cancer has returned after a prior CD19-targeted treatment. The therapy targets several other proteins on cancer cells to try to stop the cancer again.
Shenzhen, GuangdongAges 6 months–75 years - NCT05584397Enrolling by invitation
Compare immune activity and HIV hidden reservoir on two treatments
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Seattle, WashingtonAges 18–65 - NCT06479317Recruiting
Combining hydroxychloroquine and dexamethasone for ITP with positive ANA
This trial tests if adding hydroxychloroquine (HCQ) to the steroid dexamethasone (DEX) works better than dexamethasone alone for adults with immune thrombocytopenia (ITP) who have a positive antinuclear antibody (ANA) blood test. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Shanghai, Shanghai MunicipalityAges 15–75 - NCT06998264Recruiting
Immune response to flu in young children
This study looks at how children's immune systems fight the flu in the nose and throat. It aims to understand why some children get very sick and others don't, which could help create better treatments and vaccines.
GenevaAges 2–5 - NCT07430579Recruiting
Adebrelimab with chemo for esophageal cancer
This trial tests adding adebrelimab (an immunotherapy drug) to standard chemotherapy for people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination helps shrink tumors before surgery.
JinanAges 18–80 - NCT07400536RecruitingPhase 3
Cadonilimab plus chemo and radiation for advanced cervical cancer
This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.
Wuhan, HubeiAges 18–70 - NCT06928233Recruiting
TNF gene study in immune TTP patients
This study looks at a specific gene (TNFAIP3) in people who have had immune-mediated thrombotic thrombocytopenic purpura (iTTP). It aims to understand how this gene might be linked to the condition. Participants will provide a blood or DNA sample for genetic testing.
MilanAges 12 years+ - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT07379151Recruiting
Long-term protection from a meningococcal vaccine
This study checks whether the MenFive™ vaccine still protects against meningococcal disease more than five years after vaccination. It aims to see how long the immune response lasts.
BamakoAges 7–36 - NCT07364305RecruitingPhase 2
Hepatic artery infusion + immunotherapy for advanced bile duct cancer
This trial tests combining a liver-directed chemotherapy infusion (HAIC) with immunotherapy to shrink advanced bile duct cancer that cannot be removed surgically. The goal is to slow tumor growth and improve survival.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04908566RecruitingPhase 2
PD-1 immunotherapy plus chemotherapy before and after gastric surgery
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT02992210RecruitingPhase 1/Phase 2
GD2-targeted CAR T-cell therapy for hard-to-remove solid tumors
This Phase 1/2 trial tests a genetically engineered CAR T-cell treatment called 4SCAR-GD2 for certain solid tumors that have a marker called GD2. It may help shrink tumors that have returned, spread, or can’t be removed with surgery after standard treatment.
Shenzhen, GuangdongAges 1–65 - NCT07295535Recruiting
Nasal immune responses to respiratory viruses in healthy and immunocompromised people
This study looks at how the nose's immune system responds to common respiratory viruses in both healthy people and those with weakened immune systems. It aims to understand how long these responses last.
Pavia, PaviaAges 18–90 - NCT02480283Recruiting
Study of cannabis smoke and lung immune response
This study compares people who smoke cannabis daily with people who have never used cannabis. It looks at how cannabis smoke affects lung stress and the lungs’ immune defenses, using health tests and urine screening to keep participants safe.
Aurora, ColoradoAges 18–55 - NCT07276425Recruiting
Dupilumab for prurigo nodularis: long-term effects
This study follows people with moderate-to-severe prurigo nodularis who are starting dupilumab. It looks at how the medicine works over time and how it affects the immune system, to help understand long-term benefits.
Utrecht, UtrechtAges 18 years+ - NCT05121025Recruiting
Study of stomach bacteria and gut microbes in Helicobacter infection
This study looks at how stomach bacteria (Helicobacter pylori) interact with the normal microbes in your gut. You may be asked to provide tissue, stool, and blood samples to help researchers understand infection and the body’s response.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT01244802Enrolling by invitation
Study of immune memory after yellow fever vaccination
This study looks at how your immune system “remembers” the yellow fever vaccine over time. It may help researchers understand long-term immune protection and how it varies between people.
Decatur, GeorgiaAges 18 years+ - NCT05053802RecruitingPhase 2
Microwave tumor ablation plus immunotherapy for multiple lung cancers
This Phase 2 trial studies whether combining microwave ablation (a procedure to destroy lung tumors) with an immune checkpoint inhibitor can control multiple early lung cancers safely. It also aims to see how well the immune treatment helps after ablation, in people whose cancers have not spread.
Shanghai, Shanghai MunicipalityAges 18–79 - NCT06635863Enrolling by invitationPhase 4
Steroids versus standard heart medications for heart inflammation
This study compares two treatment strategies for people with unexplained heart failure and irregular heartbeats caused by inflammation: one group gets standard heart medications plus an immune-suppressing steroid (prednisone), and the other gets standard medications alone. Doctors want to see whether adding steroids helps improve heart function and control dangerous heart rhythms.
Phoenix, ArizonaAges 18 years+
Hear when a new Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunity?
- Yes. Clin2 currently lists 1,065 recruiting immunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.